Prof Chris Ormandy

Prof Chris Ormandy

Lab Head - Cancer Biology

Principal Research Fellow

Conjoint/Adjunct Role(s)

Conjoint Professor, St Vincent's Clinical School, Faculty of Medicine, UNSW Australia

Prof Chris Ormandy completed his undergraduate studies at the University of Sydney in 1984 and his PhD at the University of New South Wales in 1992.

In 2003 Chris was the NHMRC CJ Martin Fellow at Institut Necker and Institut Pasteur Paris.  In 2006 he moved back to Australia and was appointed as a senior scientist at the Kolling Institute, Royal North Shore Hospital.  In 2007 Chris joined the Garvan Institute of Medical research as a Research Group Leader.

Chris is currently President elect and board Member of the International Association for Breast Cancer Research, an Executive member of the Scientific Advisory Board of the National Breast Cancer Foundation Austraila and a National Health and Medical Research Council Research Fellow.

Research Interests

The effect of the transcription factor Elf5 on progenitor cell fate decisions during mammary development, aspects of breast cancer phenotype such as sensitivity to estrogens, development of antiestrogen resistance, molecular subtype, epithelial to mesenchymal transition and metastatic activity
The relative contributions of oncogenic insult and cell of origin to tumour phenotype
The role of pathogen activated molecular pattern receptors in mammary development
The regulation of mammary development and function by prolactin

Awards and Honours

Senior Research Fellowship NHMRC Australia


1992 - PhD, University of New South Wales - Australia
1984 - BSc (Hons), University of Sydney - Australia

Selected Publications

Gallego-Ortega D, Oakes SR, and Ormandy CJ. Elf5 and breast cancer. Future Medicine Breast Cancer Management. 2013; 2:489-498

Lee, H.J., D. Gallego-Ortega, A. Ledger, D. Schramek, P. Joshi, M.M. Szwarc, C. Cho, J.P. Lydon, R. Khokha, J.M. Penninger, and C.J. Ormandy, Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development, 2013; 140(7):1397-1401.

Lee, H.J. and C.J. Ormandy, Elf5, hormones and cell fate. Trends in Endocrinology and Metabolism, 2012; 23(6):292-298.

Kalyuga, M., D. Gallego-Ortega, H.J. Lee, D.L. Roden, M.J. Cowley, C.E. Caldon, A. Stone, S.L. Allerdice, F. Valdes-Mora, R. Launchbury, A.L. Statham, N. Armstrong, M.C. Alles, A. Young, A. Egger, W. Au, C.L. Piggin, C.J. Evans, A. Ledger, T. Brummer, S.R. Oakes, W. Kaplan, J.M.W. Gee, R.I. Nicholson, R.L. Sutherland, A. Swarbrick, M.J. Naylor, S.J. Clark, J.S. Carroll, and C.J. Ormandy, ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. Plos Biology, 2012;10(12): e1001461.

Lee, H.J., R.A. Hinshelwood, T. Bouras, D. Gallego-Ortega, F. Valdes-Mora, K. Blazek, J.E. Visvader, S.J. Clark, and C.J. Ormandy, Lineage Specific Methylation of the Elf5 Promoter in Mammary Epithelial Cells. Stem Cells, 2011; 29(10):1611-1619.

Alles, M.C., M. Gardiner-Garden, D.J. Nott, Y.X. Wang, J.A. Foekens, R.L. Sutherland, E.A. Musgrove, and C.J. Ormandy, Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the "Basal" Breast Cancer Subgroup. Plos One, 2009; 4(3):e4710.

Oakes, S.R., M.J. Naylor, M.L. Asselin-Labat, K.D. Blazek, M. Gardiner-Garden, H.N. Hilton, M. Kazlauskas, M.A. Pritchard, L.A. Chodosh, P.L. Pfeffer, G.J. Lindeman, J.E. Visvader, and C.J. Ormandy, The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes & Development, 2008; 22(5):581-586.

Oakes, S.R., F.G. Robertson, J.G. Kench, M. Gardiner-Garden, M.P. Wand, J.E. Green, and C.J. Ormandy, Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene, 2007; 26(4):543-553.

Harris, J., P.M. Stanford, K. Sutherland, S.R. Oakes, M.J. Naylor, F.G. Robertson, K.D. Blazek, M. Kazlauskas, H.N. Hilton, S. Wittlin, W.S. Alexander, G.J. Lindeman, J.E. Visvader, and C.J. Ormandy, Socs2 and Elf5 mediate prolactin-induced mammary gland development. Molecular Endocrinology, 2006; 20(5):1177-1187.

Naylor, M.J., E. Ginsburg, T.P. Iismaa, B.K. Vonderhaar, D. Wynick, and C.J. Ormandy, The neuropeptide galanin augments lobuloalveolar development. Journal of Biological Chemistry, 2003; 278(31):29145-29152.

Brisken, C., S. Kaur, T.E. Chavarria, N. Binart, R.L. Sutherland, R.A. Weinberg, P.A. Kelly, and C.J. Ormandy, Prolactin controls mammary gland development via direct and indirect mechanisms. Developmental Biology, 1999; 210(1):96-106.

Ormandy, C.J., A. Camus, J. Barra, J.D. Damotte, B. Lucas, H. Buteau, M. Edery, N. Brousse, C. Babinet, N. Binart, and P.A. Kelly, Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes & Development, 1997; 11(2):167-178.

Prof Chris Ormandy